Financial Performance - The company's operating revenue for 2023 was CNY 581,241,824.41, an increase of 4.48% compared to the previous year[4]. - The net profit attributable to shareholders decreased by 2.63% to CNY 54,000,095.32, while the net profit excluding non-recurring gains and losses fell by 21.83% to CNY 38,957,946.87[6]. - Basic earnings per share decreased by 8.75% to CNY 0.73, primarily due to a decline in net profit and the dilution effect from the issuance of 20 million new shares[8]. Assets and Equity - Total assets at the end of the reporting period were CNY 676,870,311.68, reflecting a growth of 31.11% from the beginning of the period[6]. - Shareholders' equity attributable to the company increased by 70.70% to CNY 507,836,432.83, with the net asset value per share rising by 32.33% to CNY 5.69[5]. - The increase in total assets and equity indicates a strong financial position, despite the challenges faced in profitability[6]. Cost and Profitability Challenges - The decline in net profit excluding non-recurring gains and losses was mainly due to increased raw material prices and higher labor and market development costs[7]. - The company plans to address the impact of rising costs and market conditions in future strategies[7]. Sales Structure Changes - The company experienced a significant change in sales structure, with a decrease in sales and revenue from isooctyl nitrate and an increase in sales and revenue from pour point depressants[6]. Financial Data Disclaimer - The company cautions that the financial data presented is preliminary and unaudited, and final figures may differ in the annual report[9].
万德股份(836419) - 2023 Q4 - 年度业绩